IL0011651580 - Common Stock
Positive Compatibility Results Reinforce Safety and Efficacy of PRF-110 in Post-Surgical Pain Management...
TEL AVIV, Israel, Sept. 10, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (
PRF-110 Demonstrates Superior Coverage and Stability in Surgical Wounds Findings Highlight PRF-110’s Competitive Edge Over Leading Pain Management...
PRFX stock results show that PainReform beat analyst estimates for earnings per share the second quarter of 2024.
TEL AVIV, Israel, Aug. 20, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (
Reaches full enrollment in the second part of Phase 3 clinical trial of PRF-110 in bunionectomy Remains on track to announce top-line data in late...
TEL AVIV, Israel, Aug. 07, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (
PRF-110 promoted normal wound healing and prevented scar formation following surgical procedures Company reaffirms it is on track to report top-line...
New process expected to significantly bolster future commercialization efforts...
TEL AVIV, Israel, July 24, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (
Top line data to be reported in the second half of 2024...
Pre-market stock movers are worth checking out on Friday as we dive into all of the biggest news moving shares this morning!
Pre-market stock movers are worth checking out on Thursday as we break down all of the hottest stock market news this morning!
TEL AVIV, Israel, May 31, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (
InvestorPlace - Stock Market News, Stock Advice & Trading Tips PainReform (NASDAQ:PRFX) just reported results for the first quarter of 2024.Pa...
PRFX stock results show that PainReform missed analyst estimates for earnings per share the first quarter of 2024.
Reaches 50% enrollment in the second part of its Phase 3 clinical trial of PRF-110 in bunionectomy Remains on track to announce top-line data in Q3 2024...
TEL AVIV, Israel, May 08, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (
TEL AVIV, Israel, April 18, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical-stage specialty...
Pre-market stock movers are worth diving into on Wednesday morning to get ready for all of the hottest news moving shares today!
TEL AVIV, Israel, April 09, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (
Remains on track to announce top-line data by mid-2024...
Reports continued enrollment in the second part of the Phase 3 clinical trial in bunionectomy Remains on track to announce top-line data by mid-2024 TEL...
TEL AVIV, Israel, Jan. 22, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (
PainReform (PRFX) files a prospectus for resale of up to 968,545 ordinary shares, however, it is not an offer to sell.
PRF-110 demonstrated superior formulation properties with respect to surface-tissue spreading...
TEL AVIV, Israel, Dec. 26, 2023 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (
Reports enrollment of first patients for the second part of Phase 3 clinical trial in bunionectomy...